IP Library › Granted Patent US 9,730,927
Granted Patent B2
US 9,730,927 · App. 14/940,802 · Granted Aug 15, 2017

Use of flibanserin in the treatment of obesity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,730,927
App. No.
14/940,802
Granted
Aug 15, 2017
Kind
B2
Abstract

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

Claims (20)

1. A pharmaceutical composition comprising a) an active substance being not flibanserin, selected from the group consisting of orlistat, phentermine, sibutramine and topiramate and pharmaceutically acceptable salts thereof and b) flibanserin, optionally in form of the free base, and/or the pharmacologically pharmaceutically acceptable acid addition salts and/or optionally in form of the hydrates and/or solvates thereof.

2. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmacologically acceptable acid addition salt thereof selected from the salts formed by the acids selected from the group consisting of succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

3. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with succinic acid.

4. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with hydrobromic acid.

5. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with acetic acid.

6. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with fumaric acid.

7. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with maleic acid.

8. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with methanesulfonic acid.

9. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with lactic acid.

10. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with phosphoric acid.

11. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with hydrochloric acid.

12. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with sulphuric acid.

13. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with tartaric acid.

14. A pharmaceutical composition according to claim 1 , wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with citric acid.

15. A pharmaceutical composition according to claim 1 , wherein the composition contains between 0.01 to 400 mg of flibanserin.

16. A pharmaceutical composition according to claim 1 , wherein the composition contains between 2.0 to 200 mg of flibanserin.

17. A pharmaceutical composition according to claim 1 , wherein the composition contains 100 mg of flibanserin.

18. A pharmaceutical composition according to claim 1 , wherein the active substance is orlistat in an amount of between about 100 mg to 400 mg.

19. A pharmaceutical composition according to claim 1 , wherein the active substance is sibutramine in an amount of between about 5 to 15 mg.

20. A pharmaceutical composition according to claim 1 , wherein the active substance is phentermine in an amount of between about 30 to 90 mg.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Apr 13, 2023
From: SPROUT PHARMACEUTICALS, INC.
To: HOLLAND, ANNE; MCGLOTHLIN, SANDRA
Reel/Frame 063320/0136 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061401/0684 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY AGREEMENT Recorded May 25, 2017
From: ALDEN OPTICAL LABORATORIES, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SPROUT PHARMACEUTICALS, INC.; SYNERGETICS USA, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 042584/0861 →